Mechanism of Defective Incretin Action in Beta Cells during Type 2 Diabetes Mellitus
2 型糖尿病期间 β 细胞中肠促胰岛素功能缺陷的机制
基本信息
- 批准号:10427438
- 负责人:
- 金额:$ 48.35万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-07-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:ADRBK1 geneAcetylcholineAffectAlpha CellAnti-Inflammatory AgentsBeta CellBindingBiochemicalBlood CirculationCell physiologyCellsChemosensitizationChronicCoupledCyclic AMPDiabetes MellitusElectrophysiology (science)EndocrineEventExocytosisFunctional disorderG-Protein-Coupled ReceptorsGLP-I receptorGTP-Binding Protein alpha Subunits, GsGTP-Binding ProteinsGastric Inhibitory PolypeptideGene ExpressionGene Expression ProfileGenetic TranscriptionGlucoseGlycerolHormonesHumanIn VitroInflammationInflammatoryIngestionInositolInsulinInterleukin-1IntestinesIslet CellIslets of LangerhansKiller CellsL CellsLeadLigandsLinkMediatingMetabolismMolecularMusNecrosisNeurotransmittersNicotinic ReceptorsNon-Insulin-Dependent Diabetes MellitusNutrientObesityOutcomePathway interactionsPatientsPeptide ReceptorPeripheralPharmacologyPhosphotransferasesPhysiologicalProinsulinPropertyReceptor SignalingRegulationResistanceRoleSerineSignal PathwaySignal TransductionSourceStimulusStructure of beta Cell of isletSystemTNF geneTNFRSF1A geneTissuesalpha-bungarotoxin receptorbasecholinergiccytokinediet-induced obesitygastric inhibitory polypeptide receptorglucagon-like peptide 1glucose receptorglycemic controlimprovedin vivoincretin hormoneinsightinsulin secretionisletmacrophagemouse modelnovelreceptorrecruitresponsetranslational impacttripolyphosphatetumor
项目摘要
PROJECT SUMMARY/ABSTRACT
The incretin-mediated potentiation of glucose-stimulated insulin secretion (GSIS) accounts for 50% of
postprandial insulin secretion and is essential for physiologic glycemic regulation. Upon nutrient stimulus, the
two principal incretin hormones glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1
(GLP-1) are secreted, respectively, from intestinal endocrine K- and L-cells and reach β-cells via the circulation,
where they bind their receptors, GIP receptor (GIPR) and GLP-1 receptor (GLP-1R) to amplify GSIS.
While circulating incretin hormone levels are not impacted by T2DM, incretin effects on β-cell GSIS are
significantly diminished in T2DM patients. However, the precise mechanisms underlying diabetes-associated
blunting of incretin signaling in β-cells remain unclear.
In T2DM, pharmacologic means to increase circulating GLP-1 levels improves GSIS and glycemic control.
In contrast, the GIP-mediated incretin effect is notably absent in T2DM; and pharmacologic means to increase
circulating GIP concentrations is not met with any GSIS improvement. The molecular mechanisms underlying
diminished response to GLP-1 and absent response to GIP in T2DM remain poorly understood.
T2DM is in part linked to a chronic inflammatory state with increased levels of local and circulating
inflammatory cytokines that negatively impact insulin action in peripheral tissues and negatively impact the
endocrine pancreas. We have therefore examined the role of pro-inflammatory cytokines that are elevated in
T2DM on incretin signaling in islet -cells. Conversely, we have also interrogated the anti-inflammatory
cholinergic signaling system through nicotinic acetylcholine receptors (nAchR) in modulating incretin signaling.
Based on our preliminary studies, we hypothesize that TNFα - signaling through its receptor TNFR1 on β-
cells - activates the Ser/Thr G-protein receptor kinase 2 (GKR2) in a non-canonical manner to suppress Gαs-
activation and cAMP synthesis by ligand activated GIPR and by GLP-1R. Thus, our findings establish a
mechanistic link between inflammatory cytokines in T2DM with diminished incretin signaling in β-cells.
Our preliminary studies also indicate that in a murine model of T2DM, stimulating the α7 nicotinic
acetylcholine receptor (α7-nAchR) reactivates GIPR signaling in β-cells to potentiate GSIS and improve
glycemia. Our mechanistic studies indicate that α7-nAchR signaling phosphorylates (TNFα-activated) GRK2 at
serine 670 to counteract its inhibitory effects on GIPR and GLP-1R-mediated cAMP synthesis.
We now seek to expand our novel and exciting findings specifically a) to understand the role of TNFR1-
GRK2-mediated signaling on in vivo β-cell function, on GIP and GLP-1R action as well as how TNFR1 signaling
modulates α-cell gene expression in the context of obesity and T2DM; b) to specifically understand the role of
GRK2 in mediating resistance to β-cell incretin action in T2DM; and c) to understand the beneficial role of anti-
inflammatory α7-nAchR signaling in β-cells in the context of T2DM.
We will use complementary in vivo and in vitro approaches to elucidate these important signaling pathways
in β-cells using newly generated unique mouse models as well as in vitro in human islets and β-cells.
The outcomes of our studies will yield important insights into how inflammatory cytokines of T2DM impact
incretin signaling and β-cell function. Our proposed studies will also provide new insights into the effects of
nicotinic acetylcholine signaling in β-cells. Finally, our studies identify potentially new receptor targets with the
potential to ameliorate β-cell dysfunction in T2DM.
.
项目摘要/摘要
胰岛素介导的葡萄糖刺激的胰岛素分泌增强(GSIS)占50%
餐后胰岛素分泌,对生理血糖调节是必不可少的。在营养刺激下,
两种主要的胰岛素激素--葡萄糖依赖的促胰岛素肽(GIP)和胰升糖素样肽-1
(GLP-1)分别由肠道内分泌K细胞和L细胞分泌,并通过循环到达β细胞,
它们与其受体GIP受体(GIPR)和GLP-1受体(GLP-1R)结合以扩增GSIS。
虽然T2 DM对循环中的胰岛素水平没有影响,但胰岛素对β细胞GSI的影响是
在T2 DM患者中显著降低。然而,与糖尿病相关的确切机制
β细胞中INTIN信号的钝化仍不清楚。
在T2 DM患者中,提高循环GLP-1水平的药物手段可改善GSIS和血糖控制。
相反,GIP介导的胰岛素效应在T2 DM中明显不存在;药物手段增加
循环的GIP浓度没有得到任何GSIS的改善。潜在的分子机制
T2 DM患者对GLP-1的反应减弱和对GIP的反应缺失仍然知之甚少。
T2 DM部分与慢性炎症状态有关,局部和循环水平增加
炎性细胞因子对周围组织中胰岛素的作用产生负面影响,并对
内分泌胰腺。因此,我们研究了促炎症细胞因子的作用,这些细胞因子在
T2 DM对胰岛细胞胰岛素信号转导的影响相反,我们也审问了消炎药
胆碱能信号系统通过烟碱型乙酰胆碱受体(NAchR)调节胰岛素信号。
根据我们的初步研究,我们假设肿瘤坏死因子α信号通过其在β上的受体TNFR 1-
细胞-以非规范方式激活丝氨酸/苏氨酸G蛋白受体激酶2以抑制GαS-
配体激活GIPR和GLP-1R激活和合成cAMP。因此,我们的发现建立了一个
T2 DM的炎性细胞因子与β细胞中INTIN信号减弱之间的机制联系。
我们的初步研究还表明,在T2 DM小鼠模型中,刺激α7尼古丁
乙酰胆碱受体(α7-nAchR)重新激活β-细胞中的GIPR信号,增强GSI并改善
血糖升高。我们的机制研究表明,α7-nAchR信号磷酸化(肿瘤坏死因子α激活)GRK2at
丝氨酸670拮抗其对GIPR和GLP-1R介导的cAMP合成的抑制作用。
我们现在寻求扩展我们的新颖和令人兴奋的发现,特别是a)了解TNFR1的作用-
GRK2介导的体内β细胞功能、GIP和GLP-1R的作用及其信号转导途径
在肥胖和T2 DM的背景下调节α细胞基因的表达;b)具体了解
GRK2在介导T2 DM对β细胞的胰岛素抵抗中的作用;以及c)了解抗GRK2的有益作用
2型糖尿病背景下α7-nAchR在β细胞中的炎性信号转导
我们将使用体内和体外互补的方法来阐明这些重要的信号通路。
在使用新产生的独特小鼠模型的β细胞中,以及在体外的人类胰岛和β细胞中。
我们的研究结果将对T2 DM的炎性细胞因子如何影响提供重要的见解
胰岛素信号与β细胞功能。我们建议的研究也将为我们提供关于
烟碱型乙酰胆碱在β细胞中的信号转导。最后,我们的研究确定了潜在的新受体靶点
改善T2 DM患者β细胞功能障碍的可能性。
。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mehboob A Hussain其他文献
Mehboob A Hussain的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mehboob A Hussain', 18)}}的其他基金
Mechanism of Defective Incretin Action in Beta Cells during Type 2 Diabetes Mellitus
2 型糖尿病期间 β 细胞中肠促胰岛素功能缺陷的机制
- 批准号:
10313849 - 财政年份:2021
- 资助金额:
$ 48.35万 - 项目类别:
Mechanism of Defective Incretin Action in Beta Cells during Type 2 Diabetes Mellitus
2 型糖尿病期间 β 细胞中肠促胰岛素功能缺陷的机制
- 批准号:
10619654 - 财政年份:2021
- 资助金额:
$ 48.35万 - 项目类别:
Hepatic endocrine suppression of the pancreatic beta-cell
胰腺β细胞的肝脏内分泌抑制
- 批准号:
8817887 - 财政年份:2014
- 资助金额:
$ 48.35万 - 项目类别:
Hepatic endocrine suppression of the pancreatic beta-cell
胰腺β细胞的肝脏内分泌抑制
- 批准号:
9671615 - 财政年份:2014
- 资助金额:
$ 48.35万 - 项目类别:
Control of hepatic and b-cell function by co-activators
共激活剂对肝细胞和 B 细胞功能的控制
- 批准号:
8010071 - 财政年份:2010
- 资助金额:
$ 48.35万 - 项目类别:
High-Throughput Screen For FDA Approved Drugs That Amplify Beta-Cell Mass In Vivo
高通量筛选 FDA 批准的体内放大 β 细胞质量的药物
- 批准号:
8045193 - 财政年份:2010
- 资助金额:
$ 48.35万 - 项目类别:
相似海外基金
Spatiotemporal dynamics of acetylcholine activity in adaptive behaviors and response patterns
适应性行为和反应模式中乙酰胆碱活性的时空动态
- 批准号:
24K10485 - 财政年份:2024
- 资助金额:
$ 48.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural studies into human muscle nicotinic acetylcholine receptors
人体肌肉烟碱乙酰胆碱受体的结构研究
- 批准号:
MR/Y012623/1 - 财政年份:2024
- 资助金额:
$ 48.35万 - 项目类别:
Research Grant
CRCNS: Acetylcholine and state-dependent neural network reorganization
CRCNS:乙酰胆碱和状态依赖的神经网络重组
- 批准号:
10830050 - 财政年份:2023
- 资助金额:
$ 48.35万 - 项目类别:
Study on biological significance of acetylcholine and the content in food resources
乙酰胆碱的生物学意义及其在食物资源中的含量研究
- 批准号:
23K05090 - 财政年份:2023
- 资助金额:
$ 48.35万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
alpha7 nicotinic acetylcholine receptor allosteric modulation and native structure
α7烟碱乙酰胆碱受体变构调节和天然结构
- 批准号:
10678472 - 财政年份:2023
- 资助金额:
$ 48.35万 - 项目类别:
Diurnal Variation in Acetylcholine Modulation of Dopamine Dynamics Following Chronic Cocaine Intake
慢性可卡因摄入后乙酰胆碱对多巴胺动力学调节的昼夜变化
- 批准号:
10679573 - 财政年份:2023
- 资助金额:
$ 48.35万 - 项目类别:
Striatal Regulation of Cortical Acetylcholine Release
纹状体对皮质乙酰胆碱释放的调节
- 批准号:
10549320 - 财政年份:2022
- 资助金额:
$ 48.35万 - 项目类别:
Differential Nicotinic Acetylcholine Receptor Modulation of Striatal Dopamine Release as a Mechanism Underlying Individual Differences in Drug Acquisition Rates
纹状体多巴胺释放的烟碱乙酰胆碱受体差异调节是药物获取率个体差异的机制
- 批准号:
10553611 - 财政年份:2022
- 资助金额:
$ 48.35万 - 项目类别:
Mechanisms of nicotinic acetylcholine receptor modulation of cocaine reward
烟碱乙酰胆碱受体调节可卡因奖赏的机制
- 批准号:
10672207 - 财政年份:2022
- 资助金额:
$ 48.35万 - 项目类别:
Structural basis of nicotinic acetylcholine receptor gating and toxin inhibition
烟碱乙酰胆碱受体门控和毒素抑制的结构基础
- 批准号:
10848770 - 财政年份:2022
- 资助金额:
$ 48.35万 - 项目类别: